Risdiplam
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Risdiplam: From Spinal Muscular Atrophy to Acne (Disease)
One-Sentence Summary
Risdiplam is an SMN2 pre-mRNA splicing modulator used to treat spinal muscular atrophy (SMA) by increasing SMN protein expression in motor neurons. The TxGNN model predicts a possible association with Acne (Disease), but this prediction is currently supported by 0 clinical trials and 0 publications, with no plausible mechanistic link identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no original indications recorded) |
| Predicted New Indication | Acne (disease) |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacology, risdiplam is an SMN2 pre-mRNA splicing modulator that increases survival motor neuron (SMN) protein expression to treat spinal muscular atrophy (SMA). Its mechanism centers on RNA splicing regulation and motor neuron preservation.
There is no established biological connection between this mechanism and acne pathophysiology, which involves sebaceous gland activity, androgen signaling, follicular inflammation, and C. acnes colonization. The predicted indication and the drug’s known mechanism operate in entirely distinct biological systems.
The TxGNN score of 99.45% is very high, but in the absence of any supporting clinical trials, literature, or mechanistic rationale, this likely reflects data sparsity or indirect graph-node associations in the knowledge graph (e.g., missing original indication data marked as [Data Gap]) rather than a true pharmacological relationship. This should be treated as a high-risk, likely false-positive prediction.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Risdiplam is not currently marketed in the reference regulatory database (market status: 未上市, 0 licenses on file). No authorization records are available to list.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5 evidence) with no clinical trials, no literature, and no plausible mechanistic link to acne. Combined with missing MOA and safety data, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (currently blocking, DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- Independent mechanistic or preclinical rationale connecting SMN2 splicing modulation to acne pathophysiology
- At minimum, exploratory/observational evidence (case reports, pharmacovigilance signals) before considering further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.